SG-293

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameSG-293

Drug Alias NameSG293

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsCluster of differentiation 8 modulators

TargetsB-lymphocyte antigen CD19Cluster of differentiation 8

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSana Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesSana Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A